1. Indications and Usage
\nPartial-Onset Seizures:
\nTreatment of patients 4 years of age and older with partial-onset seizures with or without secondary generalization as adjunctive therapy.
\nPrimary Generalized Tonic-Clonic Seizures:
\nTreatment of patients 12 years of age and older with primary generalized tonic-clonic seizures as adjunctive therapy.
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Oral Use ONLY.
\nRecommended Dosage:
\nStarting Dose: 2 mg once daily at bedtime.
\nTitration: Dose can be increased in 2 mg increments at intervals of no less than 1 week (or 2 weeks depending on co-administered drugs).
\nMaintenance: Recommended dose is 4 mg to 12 mg once daily.
\nMaximum Dose: 12 mg once daily.
\nAdministration:
\nSwallow tablets whole; do not chew, crush, or split.
\nTake once daily at bedtime (to minimize CNS side effects).
\n3. Mechanism of Action
\nAMPA Receptor Antagonism:
\nPerampanel is a selective, non-competitive antagonist of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor.
\nBlocking Excitation:
\nGlutamate is the major excitatory neurotransmitter in the brain. By blocking AMPA receptors on the postsynaptic membrane, perampanel inhibits glutamate-mediated neuronal excitation.
\nSeizure Control:
\nThis inhibition reduces the excessive neuronal firing associated with seizure propagation.
\n4. Safety and Warnings
\nSerious Psychiatric and Behavioral Reactions (Boxed Warning):
\nSevere psychiatric and behavioral adverse reactions (e.g., aggression, hostility, irritability, and homicidal ideation) have occurred.
\nAction: Monitor patients for emergence or worsening of these symptoms. Discontinue immediately if severe reactions occur.
\nDizziness and Coordination Problems:
\nMay cause dizziness, ataxia, and somnolence. Caution patients regarding driving or operating machinery.
\nSuicidal Behavior:
\nMonitor for emergence of suicidal thoughts or behavior.
\nDrug Interactions:
\nCYP3A4 Inducers: Drugs like carbamazepine, phenytoin, or oxcarbazepine significantly decrease perampanel exposure (approx. 50\u201367%), requiring dose adjustments (up to 12 mg max).
\nOral Contraceptives: At doses \u226512 mg\/day, it may reduce the efficacy of hormonal contraceptives (e.g., levonorgestrel).
\n5.Adverse Reactions
\nMost Common:
\nDizziness, somnolence, headache, fatigue, irritability, nausea, vomiting, weight gain, diarrhea, and fall.
\n6.Drug Interactions
\nMetabolism:
\nPrimarily metabolized by CYP3A4\/5.
\nContraindications\/Precautions:
\nAvoid strong CYP3A4 inducers (e.g., rifampin).
\nCaution with CNS depressants (e.g., alcohol, opioids) due to additive effects.
\n7.Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Perampanel.
\nAvailable Strength: 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg tablets.
\nAppearance: Film-coated tablets (color varies by strength).
\nStorage: Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u201330\u00b0C (59\u201386\u00b0F).<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u536b\u514b\u6cf0 \u00ae(Fycompa\u00ae)
\nGeneric Name: Perampanel
\nStrength: 4 mg per tablet
\nManufacturer: Eisai Co., Ltd. (Kawashima Factory)
\nMarketing Authorization Holder: Eisai Europe Limited (Domestic contact entity: Eisai China Co., Ltd.)
\nApproval Date in China: September 29, 2019
\nRegistration Number: \u56fd\u836f\u51c6\u5b57H20190054
\nStorage: Store at temperatures not exceeding 25\u00b0C (77\u00b0F). Keep the tablets in the original blister pack to protect from light and moisture. Refer to the package insert for detailed storage and handling instructions.<\/p>\n
Price&Cost:Contact Us now for the best price of Perampanel \uff08Fycompa\uff09<\/p>\n","protected":false},"featured_media":4064,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[92],"product_cat":[27],"product_tag":[],"class_list":["post-4063","product","type-product","status-publish","has-post-thumbnail","product_brand-eisai","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n